NBS Present at Multiple Conferences in November NEW

New Post Public Reply Private Reply Replies (0) Message Board

Nov 2, 2012 at 9:42 AM

[b]NBS >> Present at Multiple Conferences in November[/b]

NEW YORK, Oct. 31, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy market, today announced that Company management and management of its subsidiary, Progenitor Cell Therapy ("PCT"), have been invited to present at multiple conferences in November.

American Heart Association – Scientific Sessions 2012

Date: November 6, 2012, 11:00 AM PST
Venue: Los Angeles Convention Center, Los Angeles, CA
Session Title: Cardiovascular Regeneration: From Bench to Clinic
Presenter: Jonathan Sackner-Bernstein, M.D., FACC, Vice President, Clinical Development and Regulatory Affairs of NeoStem will present an abstract titled "Predictors of Response to Intracoronary Delivery of CD34+CXCR4+ Enriched Bone Marrow Derived Stem Cells (AMR-001) Early After STEMI"
2012 ISPE Annual Meeting: Global GMP Solutions through Innovation and Transformation

Date: November 12, 2012, 3:30 PM PST
Venue: Marriott Marquis, San Francisco, CA
Presenter: Sanjin Zvonic, Ph.D., Director of Technology and Business Development of PCT, will speak on "Immunotherapies and Tissue Culture Manufacturing Technologies" within the Biotechnology Executive Series Session
Lazard Capital Markets 9th Annual Healthcare Conference

Date: November 14, 2012, 10:00 AM EST
Venue: The Pierre Hotel, New York, NY
Presenter: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem will give a company presentation.
New York Society of Security Analysts' 16th Annual "Investing in Life Sciences" Conference

Date: November 29, 2012, 11:15 AM EST
Venue: NYSSA Conference Center, New York, NY
Presenters: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem will give a company presentation.
About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

For more information, please visit www.neostem.com.

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its contract development and manufacturing ("CDMO") business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. Forward looking statements also include statements with respect to satisfying all conditions to closing the disposition of Erye, including receipt of all necessary regulatory approvals in the PRC. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including but not limited to matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

Trout Group
Gitanjali Jain Ogawa, Vice President
Phone: +1-646-378-2949
Email:

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Laboratoires Pierre Fabre and XtalPi Unite for AI-Driven Drug Hunt

An Unexpected Turn in the Drug Discovery Arena It's not every day that you see a historic French pharma powerhouse and a cutting-edge Chinese tech firm join forces. On one side, we've got Laboratoires Pierre Fabre, steeped in the history and nitty-gritty of clinical drug development. On the other, we’ve got XtalPi Holdings Limited (2228.HK), bringing their high-tech AI...

West Virginia's Water Upgrade: AWK's Strategic Moves

Building a Water Infrastructure with Purpose Well, they ain't just whistling Dixie down in Ranson, West Virginia. American Water's been busy putting their money where their mouth is with this new 816,000-gallon tank. When you look at the bigger picture, it ain't just about a shiny new water storage toy. Nah, this is about setting the stage for long-term resilience in the...

NAMSA, AMS Partner to Fast-Track Tissue-Healing Tech

Streamlining the Path to Market I tell you, the medical device sector is no walk in the park these days. Between the regulators breathing down your neck and the endless red tape, getting a new product from the lab to the hospital floor can feel like running a marathon in quicksand. That's why this deal between NAMSA and Advanced Medical Solutions (AMS) has me taking a...

Paratus Energy Lands Petrobras Tender, Ties Finalizing

Seagems Joint Venture Snags Petrobras Contract Let’s dive headfirst into this business update, because this one's got teeth, folks. Petrobras, the big dog in Brazil’s oil arena, has given the green light to Seagems’ bid, a joint venture half-owned by Paratus Energy Services Ltd. The target? A hefty pipe-laying support vessel (PLSV) contract starting in 2028. But...

KT&G Launches Heated Tobacco in Kazakhstan's Market

KT&G Lights Up Kazakhstan In a bold move, KT&G is laying down the gauntlet in Kazakhstan's tobacco market, introducing its cutting-edge heated tobacco gizmo and a handful of sleek FAIIM sticks. Launching this October, these aren't just any devices—they're the FLEX locals have been waiting for, rebranded from South Korea's lil AIBLE and AIIM but made to fit right in with...

Korean 'Glocal' Districts Entice U.S. Tourists with Local Flavor

Gwangju's Dongmyeong-dong is like the neighborhood artists and hipsters flock to in New York—except it’s got a Korean twist. Nestled in the Jeonnam region, this place is hot on American tourists' radar for its spicy mix of local culture, unique eats, and shops that scream individuality. It's becoming a magnet for folks who want to get a taste of Korean life but with a...

Middleby Under Scrutiny: Shareholder Investigation Alert

Middleby Shareholders in the Crosshairs There's hot soup boiling over at The Middleby Corporation (NASDAQ: MIDD). A shareholder investigation is underway, spearheaded by Purcell & Lefkowitz LLP, a firm that jumps into the fray when there’s a whiff of fiduciary breaches in corporate dealings. As I see it, this kind of legal sniffing around often stirs the pot—raising...

ASTS Faces Class Action; Investors Beware of Pitfalls

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

UAE Pioneers eATA Carnet System Beyond Europe

Breaking Tradition with Digital Innovation Well, who would’ve thought? The UAE just leapt ahead in the trade game, becoming the first to roll out the eATA Carnet system beyond the cozy confines of Europe. This isn’t some run-of-the-mill tech rollout, folks. It’s a digital revolution in how temporary imports are handled—goodbye paper, hello efficiency! With this...

FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...